Skip to search formSkip to main contentSkip to account menu

Siplizumab

Known as: anti-CD2 monoclonal antibody 
A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

MEDI507
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas
Mature Tand natural killer (NK)-cell neoplasms are a heterogeneous group of diseases, accounting for roughly 10% of non-Hodgkin… 
Review
2012
Review
2012
Novel and emerging drugs for rarer chronic lymphoid leukaemias.
Rarer chronic lymphoid leukaemias represent a challenge to the clinicians due to the limited information on their pathogenesis… 
2009
2009
Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease
Background. Acute graft-versus-host disease (GVHD) is a major complication of both bone marrow and hematologic stem cell… 
2008
2008
Long-term safety profile of siplizumab, a humanized anti-CD2 monoclonal antibody, in subjects with chronic plaque psoriasis
Background: Prolonged depletion of activated T cells via targeted therapy may reduce disease activity in chronic plaque psoriasis… 
Review
2007
Review
2007
EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.
Epstein Barr virus (EBV) has the capacity to transform B lymphocytes and in the setting of immunosuppression increases the risk… 
2006
2006
Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes.
Siplizumab is a humanized monoclonal antibody that selectively binds human CD2 (huCD2), which is expressed on virtually all cells… 
2002
2002
Siplizumab: Antipsoriatic: Treatment of transplant rejection
Psoriasis is a chronic autoimmune inflammatory skin disease for which there is no known cure. The disorder is known to be T-cell… 
2002
2002
Gateways to Clinical Trials: July-August 2002
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2001
2001
Siplizumab studies show safety as psoriasis Tx
In three studies for safety, patients show improvement in psoriasis as measured by PASI score 
1997
1997
Treatment of rat hemiparkinson model with xenogeneic neural transplantation: Tolerance induction by anti‐T‐cell antibodies
To obtain basic knowledge for the application of xenogeneic neural transplantation to patients with Parkinson's disease, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)